NASDAQ · Biotechnology · USD
Eupraxia Pharmaceuticals Inc. (EPRX) Stock Analysis
Eupraxia Pharmaceuticals Inc. (EPRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
EPRX Key Statistics
As of Oct 21, 2026Trading
- Open
- $7.65
- Previous Close
- $7.59
- Day's Range
- 7.56–7.76
- 52-Week Range
- 5.25–9.32
- Volume
- 348.31K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.22
Valuation
- Market Cap
- $510.75M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.02
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$38.58M
- Shares Outstanding
- 66.07M
- 1-Year Return
- +40.80%
Dividend and dates
- Earnings Date
- November 3, 2026estimated
- Avg Volume
- 643.06K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, EPRX closed at $7.73, +40.80% over 1 year.
Eupraxia Pharmaceuticals Inc. (EPRX) has a market capitalization of $510.75M.
In fiscal 2025, EPRX reported revenue of $0.00.
EPRX Stock Return by Calendar Year
Eupraxia Pharmaceuticals Inc. (EPRX) return since Apr 2024: what $10,000 became
- 1 year
- $10,000 $14,080
- +40.80%
- Since Apr 2024
- $10,000 $26,203
- +162.03%
If you had invested $10,000 in Eupraxia Pharmaceuticals Inc. (EPRX) at the close on April 5, 2024, the earliest close on record here, it would have been worth $26,203 at the close on October 21, 2026: +162.03% in total, +46.04% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +2.38% |
| 2025 | +138.17% |
| 2024 (partial year) | +7.46% |
As of October 21, 2026.
EPRX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$38.58M | — |
| 2024 | $0.00 | −$25.50M | — |
| 2023 | $0.00 | −$28.22M | — |
| 2022 | $0.00 | −$18.49M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$38.43M | −$38.58M | — |
| 2024 | $0.00 | — | −$27.00M | −$25.50M | — |
| 2023 | $0.00 | — | −$27.85M | −$28.22M | — |
| 2022 | $0.00 | — | −$17.62M | −$18.49M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
YahooEupraxia Reaches Its Target Enrollment Of 120 Patients In Phase 2b Placebo-Controlled Blinded Portion Of RESOLVE Trial
BenzingaEupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
YahooHC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target
BenzingaEupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients
YahooEupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Yahoo
All 10 articles ↓Show fewer ↑
Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
BenzingaEupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
YahooEupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
YahooEupraxia Pharmaceuticals Q2 EPS $(0.23), Inline
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B